Re: Pentosan polysulfate and a pigmentary maculopathy: causation versus correlation?

IF 1.2 4区 医学 Q3 UROLOGY & NEPHROLOGY Canadian Journal of Urology Pub Date : 2023-12-01
Robert J Evans, Raymond Xu
{"title":"Re: Pentosan polysulfate and a pigmentary maculopathy: causation versus correlation?","authors":"Robert J Evans, Raymond Xu","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>How should a conscientious physician advise patients with Interstitial Cystitis /Bladder Pain Syndrome (IC/BPS) when they want to know if taking Pentosan Polysulfate Sodium (PPS) will lead to loss of vision? Ever since the initial report from Pearce et al in 2018 suggesting that PPS usage can lead to the development of pigmented maculopathy (PM), my patients have been inundated with solicitations from attorneys looking to sign up clients for class action lawsuits.1 While there have been additional reports suggesting a relationship between PPS exposure and the development of PM, Ludwig et al found that there was no difference in the rate of macular disease between patients with documented IC/BPS who had taken PPS and those with IC/BPS with no history of PPS use.2 The large size of Ludwig's study certainly suggests that PPS may not cause PM to develop, and if the rate of PM in the IC population is higher than in controls, it may be due to the disease itself and not from the medication. In this manuscript, Proctor clearly describes the immune inflammatory response that is responsible for the development of the bladder damage seen with IC/BPS. Also, he describes how inflammatory mediators can enter the blood stream and might be a potential cause for the development of PM.3 This is a thought-provoking hypothesis that demands further evaluation. I have prescribed PPS since its approval and have many patients who feel it is an essential part of their IC treatment regimen. There is no other prescription medication that functions in the same fashion. I require them to follow the FDA recommendations for annual eye exams to look for PM development. I also advise patients that as they improve, we will discuss dose reduction and even discontinuation if their IC symptoms have abated. By following these suggestions, one should be able to continue to prescribe PPS for appropriate patients while carefully monitoring them for PM. I found this article extremely informative and will refer to it when counseling patients about IC/BPS and PPS.</p>","PeriodicalId":56323,"journal":{"name":"Canadian Journal of Urology","volume":"30 6","pages":"11740"},"PeriodicalIF":1.2000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Urology","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

How should a conscientious physician advise patients with Interstitial Cystitis /Bladder Pain Syndrome (IC/BPS) when they want to know if taking Pentosan Polysulfate Sodium (PPS) will lead to loss of vision? Ever since the initial report from Pearce et al in 2018 suggesting that PPS usage can lead to the development of pigmented maculopathy (PM), my patients have been inundated with solicitations from attorneys looking to sign up clients for class action lawsuits.1 While there have been additional reports suggesting a relationship between PPS exposure and the development of PM, Ludwig et al found that there was no difference in the rate of macular disease between patients with documented IC/BPS who had taken PPS and those with IC/BPS with no history of PPS use.2 The large size of Ludwig's study certainly suggests that PPS may not cause PM to develop, and if the rate of PM in the IC population is higher than in controls, it may be due to the disease itself and not from the medication. In this manuscript, Proctor clearly describes the immune inflammatory response that is responsible for the development of the bladder damage seen with IC/BPS. Also, he describes how inflammatory mediators can enter the blood stream and might be a potential cause for the development of PM.3 This is a thought-provoking hypothesis that demands further evaluation. I have prescribed PPS since its approval and have many patients who feel it is an essential part of their IC treatment regimen. There is no other prescription medication that functions in the same fashion. I require them to follow the FDA recommendations for annual eye exams to look for PM development. I also advise patients that as they improve, we will discuss dose reduction and even discontinuation if their IC symptoms have abated. By following these suggestions, one should be able to continue to prescribe PPS for appropriate patients while carefully monitoring them for PM. I found this article extremely informative and will refer to it when counseling patients about IC/BPS and PPS.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
关于多硫酸戊聚糖和色素性黄斑病变:因果关系还是相关关系?
当间质性膀胱炎/膀胱疼痛综合征(IC/BPS)患者想知道服用多硫酸戊聚糖钠(PPS)是否会导致视力下降时,作为一名有良知的医生应该如何向他们提供建议?自从 Pearce 等人在 2018 年首次报告指出使用 PPS 可导致色素性黄斑病变(PM)的发生后,我的患者就收到了大量律师的邀约,希望为客户报名参加集体诉讼1。2 路德维希的研究规模很大,这无疑表明 PPS 可能不会导致黄斑病变的发生,如果 IC 患者中黄斑病变的发生率高于对照组,那可能是疾病本身的原因,而非药物所致。在这篇手稿中,普罗克特清楚地描述了免疫性炎症反应是导致 IC/BPS 膀胱损伤的原因。此外,他还描述了炎症介质如何进入血液,并可能成为诱发 PM 的潜在原因。自 PPS 获批以来,我一直在处方 PPS,许多患者都认为它是 IC 治疗方案中不可或缺的一部分。没有其他处方药具有相同的功能。我要求他们按照美国食品及药物管理局的建议,每年进行一次眼部检查,以发现 PM 的发展情况。我还建议患者,随着病情的好转,如果 IC 症状减轻,我们可以讨论减少剂量,甚至停药。通过遵循这些建议,我们应该能够继续为合适的患者处方 PPS,同时仔细观察他们是否出现 PM。我认为这篇文章信息量非常大,在向患者提供有关 IC/BPS 和 PPS 的咨询时,我将参考这篇文章。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Canadian Journal of Urology
Canadian Journal of Urology UROLOGY & NEPHROLOGY-
CiteScore
1.90
自引率
0.00%
发文量
86
审稿时长
6-12 weeks
期刊介绍: The CJU publishes articles of interest to the field of urology and related specialties who treat urologic diseases.
期刊最新文献
A Chief Wellness Officer, Every Hospital Should Have One; Marlon Brando Was Right. Artificial intelligence improves urologic oncology patient education and counseling. Factors associated with surgical refusal and non-surgical candidacy in stage 1 kidney cancer: a National Cancer Database (NCDB) analysis. How I Do It:  EnPlace sacrospinous ligament fixation. Implications of MRI contrast enhancement following focal prostate cancer cryoablation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1